Phase IIa Clinical Trial: Feasibility Study on Non-Invasive Simultaneous Hyperpolarized [1-13C]Pyruvate Magnetic Resonance Spectroscopy and 18F-FDG PET (hyperPET) for Metabolic Imaging in Patients with Cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516131-28-00

Enrollment

Registered

2024-08-28

Start date

2022-04-18

Completion date

Unknown

Last updated

2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, neuroendocrine neoplasms, lymphomas, sarcomas

Brief summary

Quantification of tumor [1-13C]Pyruvate to [1-13C]Lactate conversion measured through dynamic conversion factors and signal ratios., Quantification of tumor uptake of 18-Flouro-deoxy-glucose measured as dynamic glucose influx (Ki) and static standardized uptake values (SUV).

Detailed description

Correlation between tumor 18-Flouro-deoxy-glucose uptakes and [1- 13C]Pyruvate to [1-13C]Lactate conversion and ex-vivo non-quantitative and quantitative expression of biomarkers involved in intracellular metabolism.

Interventions

DRUGFluor-18-FDG

DRUG400 MBq-210 GBq

DRUGinjektionsvreske Fludeoxyglucose (18F)

DRUGHyperpolarized [1-13C]pyruvate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Quantification of tumor [1-13C]Pyruvate to [1-13C]Lactate conversion measured through dynamic conversion factors and signal ratios., Quantification of tumor uptake of 18-Flouro-deoxy-glucose measured as dynamic glucose influx (Ki) and static standardized uptake values (SUV).	—

Secondary

Measure	Time frame
Correlation between tumor 18-Flouro-deoxy-glucose uptakes and [1- 13C]Pyruvate to [1-13C]Lactate conversion and ex-vivo non-quantitative and quantitative expression of biomarkers involved in intracellular metabolism.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026